These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 36866631)
1. The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [ 18 F]-fluorodeoxyglucose PET/computed tomography. Berberich C; Mustafa M; Zhuwu Y; Gaa J; Krackhardt A; Nekolla SG Melanoma Res; 2023 Jun; 33(3):199-207. PubMed ID: 36866631 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of baseline metabolic tumor volume measured on Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479 [TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160 [No Abstract] [Full Text] [Related]
7. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292 [TBL] [Abstract][Full Text] [Related]
8. Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. Wagner T; Meyer N; Zerdoud S; Julian A; Chevreau C; Payoux P; Courbon F Br J Dermatol; 2011 Jun; 164(6):1235-40. PubMed ID: 21332457 [TBL] [Abstract][Full Text] [Related]
9. Metabolic parameters of [ Markus M; Sartor H; Bjurberg M; Trägårdh E Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Nakamoto R; Zaba LC; Rosenberg J; Reddy SA; Nobashi TW; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2787-2795. PubMed ID: 32296882 [TBL] [Abstract][Full Text] [Related]
12. Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma. Ellebaek E; Schina A; Andersen R; Hendel HW; Svane IM; Donia M Int J Cancer; 2022 Jun; 150(11):1870-1878. PubMed ID: 35001363 [TBL] [Abstract][Full Text] [Related]
13. Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661 [TBL] [Abstract][Full Text] [Related]
14. Can Baseline [ Bianchi A; De Rimini ML; Sciuto R; Annovazzi A; Di Traglia S; Bauckneht M; Lanfranchi F; Morbelli S; Nappi AG; Ferrari C; Rubini G; Panareo S; Urso L; Bartolomei M; D'Arienzo D; Valente T; Rossetti V; Caroli P; Matteucci F; Aricò D; Bombaci M; Caponnetto D; Bertagna F; Albano D; Dondi F; Gusella S; Spimpolo A; Carriere C; Balma M; Buschiazzo A; Gallicchio R; Storto G; Ruffini L; Scarlattei M; Baldari G; Cervino AR; Cuppari L; Burei M; Trifirò G; Brugola E; Zanini CA; Alessi A; Fuoco V; Seregni E; Deandreis D; Liberini V; Moreci AM; Ialuna S; Pulizzi S; Evangelista L Cancer Biother Radiopharm; 2023 May; 38(4):256-267. PubMed ID: 37098169 [No Abstract] [Full Text] [Related]
15. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma. Liu DD; Li J; Li X; Xie L; Qin L; Peng F; Cheng MH J Gynecol Oncol; 2019 Nov; 30(6):e89. PubMed ID: 31576685 [TBL] [Abstract][Full Text] [Related]
18. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[ Nakamoto R; C Zaba L; Rosenberg J; Arani Reddy S; W Nobashi T; Ferri V; Davidzon G; Mari Aparici C; Nguyen J; Moradi F; Iagaru A; Lewis Franc B Mol Imaging Biol; 2021 Feb; 23(1):139-147. PubMed ID: 32789649 [TBL] [Abstract][Full Text] [Related]
19. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters. Chang S; Kim SJ Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846 [TBL] [Abstract][Full Text] [Related]
20. Role of FDG-PET in the assessment of survival prognosis in melanoma. Pleiss C; Risse JH; Biersack HJ; Bender H Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]